본 연구에서는 배양 체계(혈청 첨가 TCM199, TALP, CRlaa 및 혈청 미첨가; IVMD101, IVF100, IVMD101)가 체외수정 또는 미세주입된 수정란의 체외 발달에 미치는 효과를 검토하였다. 또한 미세주입에 사용하는 GFP유전자의 양 및 미세주입 수정란에서 형광발현 양상을 검토하였다. 체외수정된 수정란의 ≥2세포기, 8세포기 및 배반포 도달율이 미세주입 수정란에 비하여 유의하게 높았다. 혈청 미첨가 배지에서의 8세포기 발달율이 수정란의 종류에 관계없이 유의하게 높았으나(p<0.05; 3.3% vs. 15.5% 및 21.4% vs. 39.4%, respectively), 배반포 도달율은 유사한 경향이었다(2.7% vs. 2.3% 및 23.0% vs. 23.6%, respectively). 한편, 2ng/uL 유전자를 미세주입한 수정란의 ≥2세포기, 8세포기 및 배반포 도달율이 4 및 8ng/uL의 것에 비하여 높은 경향이었다. 미세주입 수정란의 형광발현율은 1세포기가2및 8세포기에 비하여 유의하게 높았으나(p<0.05), 4세포기 및 배반포 단계와는 차이가 없었다.

The effects of additions/deletions in glycosylated residues of recombinant human EPO (rhEPO) produced in CHO-K1 on their secretion were examined. hEPO cDNA was amplified from human liver mRNA and cloned into the pCR2.1 TOPO. Using overlapping-extension site-directed mutagenesis method, glycosylation sites at 24th, 38th, 83rd, and 126th were respectively or accumulatively removed by substituting its asparagine (or serine) with glutamine. To add novel glycosylation sites, 69 and 105th leucine was mutated to asparagine. Mutant and wild type rhEPO constructs were cloned into the pcDNA3 expression vector with CMV promoter and transfected into CHO cell line, CHO-K1, to produce mutant rhEPO mutant rhEPO proteins. Enzyme-linked immunosorbant assay (ELISA) and Western analysis with monoclonal anti-EPO antibody were performed using supernatants of the cultures showing transient and stable expressions respectively. Addition of novel glycosylation reduced rhEPO secretion dramatically while deletion mutants had little effect except some double deletion mutants (△24/83 and △38/83) and triple mutant (△24/38/83). This fact suggests that not single but combination of changes in glycosyl groups affect secretion of rhEPO in cell culture, possibly via changes in their conformations.